Orasure Tech Inc (OSUR) 6.77 $OSUR
OraSure Technologies to Present at the Canaccord Genuity 36th Annual Growth Conference
GlobeNewswire - Mon Aug 01, 5:00AM CDT
OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Canaccord Genuity 36 Annual Growth Conference in Boston, Massachusetts. The conference will be simultaneously webcast over the Internet.
OSUR: 6.77 (-0.05)
Medical Instruments & Supplies Equities Roundup -- Endologix, Becton Dickinson, Waters, and OraSure Technologies
PR Newswire - Thu Jun 09, 7:25AM CDT
On Wednesday, June 08, 2016, the NASDAQ Composite ended the trading session at 4,974.64, up 0.26%; the Dow Jones Industrial Average advanced 0.37% to finish at 18,005.05; and the S&P 500 closed at 2,119.12, up 0.33%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Endologix Inc. (NASDAQ: ELGX), Becton, Dickinson and Company (NYSE: BDX), Waters Corporation (NYSE: WAT), and OraSure Technologies Inc. (NASDAQ: OSUR). Learn more about these stocks by accessing their free trade alerts at:
BDX: 175.28 (-0.72), ELGX: 14.10 (-0.01), WAT: 159.45 (+0.52), OSUR: 6.77 (-0.05)
Uptrend Call Working As OraSure Technologies Stock Rises 21.3% (OSUR)
Comtex SmarTrend(R) - Tue Jun 07, 1:29AM CDT
SmarTrend identified an Uptrend for OraSure Technologies (NASDAQ:OSUR) on February 10th, 2016 at $6.52. In approximately 4 months, OraSure Technologies has returned 21.26% as of today's recent price of $7.90.
OSUR: 6.77 (-0.05)
OraSure Technologies to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Tue May 31, 5:00AM CDT
OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Jefferies 2016 Healthcare Conference in New York. The conference will be simultaneously webcast over the Internet.
OSUR: 6.77 (-0.05)
Looking for a Growth Stock? Why It is Time to Focus on OraSure Technologies (OSUR)
Zacks Equity Research - Zacks Investment Research - Tue May 24, 8:48AM CDT
OraSure Technologies (OSUR) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Growth perspective.
OSUR: 6.77 (-0.05)
Boston Scientific (BSX): Q1 Earnings Beat amid CRM Woes
Zacks Equity Research - Zacks Investment Research - Thu May 12, 7:18AM CDT
On May 11, 2016, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX). The stock currently carries a Zacks Rank #2 (Buy).
BSX: 24.43 (+0.15), LMAT: 17.31 (+0.11), NUVA: 62.75 (+0.55), OSUR: 6.77 (-0.05)
OraSure Technologies to Hold Virtual Annual Meeting of Stockholders
GlobeNewswire - Tue May 10, 5:44AM CDT
OraSure Technologies, Inc. (NASDAQ:OSUR), announced that its 2016 Annual Meeting of Stockholders will be a completely virtual meeting, conducted as a live webcast beginning at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time) on Tuesday, May 17, 2016.
OSUR: 6.77 (-0.05)
OraSure Announces 2016 First Quarter Financial Results
GlobeNewswire - Wed May 04, 3:00PM CDT
OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its consolidated financial results for the first quarter ended March 31, 2016.
OSUR: 6.77 (-0.05)
OraSure Technologies to Present at the UBS 2016 Global Healthcare Conference
GlobeNewswire - Tue May 03, 5:00AM CDT
OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the UBS 2016 Global Healthcare Conference in New York. The conference will be simultaneously webcast over the Internet.
OSUR: 6.77 (-0.05)
OraSure Technologies Appoints New Chief Science Officer
GlobeNewswire - Fri Apr 15, 5:00AM CDT
OraSure Technologies, Inc. (NASDAQ:OSUR) announced today that Michael Reed, Ph.D. has been named as the Company's Senior Vice President of Research and Development and Chief Science Officer. He will begin working at the Company on April 18, 2016.
OSUR: 6.77 (-0.05)
OraSure Technologies Earnings Conference Call Invitation
GlobeNewswire - Wed Apr 13, 5:00AM CDT
OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular earnings conference call covering 2016 first quarter financial results, 2016 second quarter financial guidance and certain business developments for 5:00 pm ET (2:00 pm PT) on Wednesday, May 4, 2016.
OSUR: 6.77 (-0.05)
CVS Health Strong on Omnicare Buyout, Integration Prospects
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 1:40PM CDT
On Apr 12, 2016, we issued an updated research report on Rhode Island-based pharmacy retail giant CVS Health Corp. (CVS).
BAX: 48.06 (+0.04), RMD: 69.41 (+0.53), CVS: 92.56 (-0.16), OSUR: 6.77 (-0.05)
C.R. Bard at 52-Week High, Product Suite Holds the Key
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 11:40AM CDT
Shares of C.R. Bard Inc (BCR) rallied to a new 52-week high of $205.52 on Apr 1, eventually closing a tad bit lower at $204.69.
BCR: 224.50 (+0.77), ALGN: 88.96 (-0.19), BAX: 48.06 (+0.04), OSUR: 6.77 (-0.05)
Thermo Fisher Steals Affymetrix Deal, Expands Antibody Line
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 10:10AM CDT
With the closure of the Affymetrix deal, Thermo Fisher(TMO) expects to enjoy an extended antibody portfolio, which will boost the company's leadership in biosciences.
TMO: 158.85 (+0.01), BAX: 48.06 (+0.04), OFIX: 47.11 (-0.29), OSUR: 6.77 (-0.05)
Medtronic Unveils NURO System in US for Overactive Bladder
Zacks Equity Research - Zacks Investment Research - Thu Mar 31, 12:30PM CDT
We believe this product launch will allow Medtronic (MDT) to overcome the issues it has been facing in its Neuromodulation business division over the past couple of quarters
MDT: 87.48 (-0.15), OFIX: 47.11 (-0.29), HRC: 53.45 (+0.02), OSUR: 6.77 (-0.05)
Mead Johnson Launches Enfinitas Product Line in China
Zacks Equity Research - Zacks Investment Research - Thu Mar 31, 12:25PM CDT
Mead Johnson Nutrition Company (MJN) recently launched its Enfinitas premium-priced product line in China.
MJN: 88.60 (-0.60), BAX: 48.06 (+0.04), HRC: 53.45 (+0.02), OSUR: 6.77 (-0.05)
Quest Diagnostics Grows Through Organic, Inorganic Means
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 3:05PM CDT
On Mar 30, 2016, we issued an updated research report on Quest Diagnostics, Inc. (DGX).
BAX: 48.06 (+0.04), DGX: 86.45 (+0.09), HRC: 53.45 (+0.02), OSUR: 6.77 (-0.05)
Cepheid Up on International Launch of Next-Gen MRSA Test
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 2:50PM CDT
Cepheid's (CPHD) Xpert MRSA NxG assay is a next-generation version of the market-leading molecular diagnostic test for Methicillin-Resistant Staphyloccus aureus (MRSA).
CPHD: 36.12 (+0.79), OFIX: 47.11 (-0.29), HRC: 53.45 (+0.02), OSUR: 6.77 (-0.05)
Stryker (SYK) Scales a 52-Week High: Right Time to Buy?
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 11:40AM CDT
Shares of Stryker Corp (SYK) rallied to a new 52-week high of $106.92 on Mar 29, eventually closing a tad bit lower at $106.87.
BAX: 48.06 (+0.04), HRC: 53.45 (+0.02), OSUR: 6.77 (-0.05), SYK: 116.40 (+0.12)
Cardiovascular Systems: Market Dynamics, Margins Strong
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 1:45PM CDT
Currently, Cardiovascular Systems (CSII) stands to gain from several favorable trends existing in the PAD as well CAD market spaces
CSII: 19.56 (-0.05), OFIX: 47.11 (-0.29), HRC: 53.45 (+0.02), OSUR: 6.77 (-0.05)
OraSure Technologies to Present at the Canaccord Genuity 36th Annual Growth Conference
GlobeNewswire - Mon Aug 01, 5:00AM CDT
OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Canaccord Genuity 36 Annual Growth Conference in Boston, Massachusetts. The conference will be simultaneously webcast over the Internet.
OSUR: 6.77 (-0.05)
Medical Instruments & Supplies Equities Roundup -- Endologix, Becton Dickinson, Waters, and OraSure Technologies
PR Newswire - Thu Jun 09, 7:25AM CDT
On Wednesday, June 08, 2016, the NASDAQ Composite ended the trading session at 4,974.64, up 0.26%; the Dow Jones Industrial Average advanced 0.37% to finish at 18,005.05; and the S&P 500 closed at 2,119.12, up 0.33%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: Endologix Inc. (NASDAQ: ELGX), Becton, Dickinson and Company (NYSE: BDX), Waters Corporation (NYSE: WAT), and OraSure Technologies Inc. (NASDAQ: OSUR). Learn more about these stocks by accessing their free trade alerts at:
BDX: 175.28 (-0.72), ELGX: 14.10 (-0.01), WAT: 159.45 (+0.52), OSUR: 6.77 (-0.05)
Uptrend Call Working As OraSure Technologies Stock Rises 21.3% (OSUR)
Comtex SmarTrend(R) - Tue Jun 07, 1:29AM CDT
SmarTrend identified an Uptrend for OraSure Technologies (NASDAQ:OSUR) on February 10th, 2016 at $6.52. In approximately 4 months, OraSure Technologies has returned 21.26% as of today's recent price of $7.90.
OSUR: 6.77 (-0.05)
OraSure Technologies to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Tue May 31, 5:00AM CDT
OraSure Technologies, Inc. (NASDAQ:OSUR) today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Jefferies 2016 Healthcare Conference in New York. The conference will be simultaneously webcast over the Internet.
OSUR: 6.77 (-0.05)
Looking for a Growth Stock? Why It is Time to Focus on OraSure Technologies (OSUR)
Zacks Equity Research - Zacks Investment Research - Tue May 24, 8:48AM CDT
OraSure Technologies (OSUR) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Growth perspective.
OSUR: 6.77 (-0.05)
Boston Scientific (BSX): Q1 Earnings Beat amid CRM Woes
Zacks Equity Research - Zacks Investment Research - Thu May 12, 7:18AM CDT
On May 11, 2016, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX). The stock currently carries a Zacks Rank #2 (Buy).
BSX: 24.43 (+0.15), LMAT: 17.31 (+0.11), NUVA: 62.75 (+0.55), OSUR: 6.77 (-0.05)
OraSure Technologies to Hold Virtual Annual Meeting of Stockholders
GlobeNewswire - Tue May 10, 5:44AM CDT
OraSure Technologies, Inc. (NASDAQ:OSUR), announced that its 2016 Annual Meeting of Stockholders will be a completely virtual meeting, conducted as a live webcast beginning at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time) on Tuesday, May 17, 2016.
OSUR: 6.77 (-0.05)
OraSure Announces 2016 First Quarter Financial Results
GlobeNewswire - Wed May 04, 3:00PM CDT
OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its consolidated financial results for the first quarter ended March 31, 2016.
OSUR: 6.77 (-0.05)
OraSure Technologies to Present at the UBS 2016 Global Healthcare Conference
GlobeNewswire - Tue May 03, 5:00AM CDT
OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the UBS 2016 Global Healthcare Conference in New York. The conference will be simultaneously webcast over the Internet.
OSUR: 6.77 (-0.05)
OraSure Technologies Appoints New Chief Science Officer
GlobeNewswire - Fri Apr 15, 5:00AM CDT
OraSure Technologies, Inc. (NASDAQ:OSUR) announced today that Michael Reed, Ph.D. has been named as the Company's Senior Vice President of Research and Development and Chief Science Officer. He will begin working at the Company on April 18, 2016.
OSUR: 6.77 (-0.05)
OraSure Technologies Earnings Conference Call Invitation
GlobeNewswire - Wed Apr 13, 5:00AM CDT
OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular earnings conference call covering 2016 first quarter financial results, 2016 second quarter financial guidance and certain business developments for 5:00 pm ET (2:00 pm PT) on Wednesday, May 4, 2016.
OSUR: 6.77 (-0.05)
CVS Health Strong on Omnicare Buyout, Integration Prospects
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 1:40PM CDT
On Apr 12, 2016, we issued an updated research report on Rhode Island-based pharmacy retail giant CVS Health Corp. (CVS).
BAX: 48.06 (+0.04), RMD: 69.41 (+0.53), CVS: 92.56 (-0.16), OSUR: 6.77 (-0.05)
C.R. Bard at 52-Week High, Product Suite Holds the Key
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 11:40AM CDT
Shares of C.R. Bard Inc (BCR) rallied to a new 52-week high of $205.52 on Apr 1, eventually closing a tad bit lower at $204.69.
BCR: 224.50 (+0.77), ALGN: 88.96 (-0.19), BAX: 48.06 (+0.04), OSUR: 6.77 (-0.05)
Thermo Fisher Steals Affymetrix Deal, Expands Antibody Line
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 10:10AM CDT
With the closure of the Affymetrix deal, Thermo Fisher(TMO) expects to enjoy an extended antibody portfolio, which will boost the company's leadership in biosciences.
TMO: 158.85 (+0.01), BAX: 48.06 (+0.04), OFIX: 47.11 (-0.29), OSUR: 6.77 (-0.05)
Medtronic Unveils NURO System in US for Overactive Bladder
Zacks Equity Research - Zacks Investment Research - Thu Mar 31, 12:30PM CDT
We believe this product launch will allow Medtronic (MDT) to overcome the issues it has been facing in its Neuromodulation business division over the past couple of quarters
MDT: 87.48 (-0.15), OFIX: 47.11 (-0.29), HRC: 53.45 (+0.02), OSUR: 6.77 (-0.05)
Mead Johnson Launches Enfinitas Product Line in China
Zacks Equity Research - Zacks Investment Research - Thu Mar 31, 12:25PM CDT
Mead Johnson Nutrition Company (MJN) recently launched its Enfinitas premium-priced product line in China.
MJN: 88.60 (-0.60), BAX: 48.06 (+0.04), HRC: 53.45 (+0.02), OSUR: 6.77 (-0.05)
Quest Diagnostics Grows Through Organic, Inorganic Means
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 3:05PM CDT
On Mar 30, 2016, we issued an updated research report on Quest Diagnostics, Inc. (DGX).
BAX: 48.06 (+0.04), DGX: 86.45 (+0.09), HRC: 53.45 (+0.02), OSUR: 6.77 (-0.05)
Cepheid Up on International Launch of Next-Gen MRSA Test
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 2:50PM CDT
Cepheid's (CPHD) Xpert MRSA NxG assay is a next-generation version of the market-leading molecular diagnostic test for Methicillin-Resistant Staphyloccus aureus (MRSA).
CPHD: 36.12 (+0.79), OFIX: 47.11 (-0.29), HRC: 53.45 (+0.02), OSUR: 6.77 (-0.05)
Stryker (SYK) Scales a 52-Week High: Right Time to Buy?
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 11:40AM CDT
Shares of Stryker Corp (SYK) rallied to a new 52-week high of $106.92 on Mar 29, eventually closing a tad bit lower at $106.87.
BAX: 48.06 (+0.04), HRC: 53.45 (+0.02), OSUR: 6.77 (-0.05), SYK: 116.40 (+0.12)
Cardiovascular Systems: Market Dynamics, Margins Strong
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 1:45PM CDT
Currently, Cardiovascular Systems (CSII) stands to gain from several favorable trends existing in the PAD as well CAD market spaces
CSII: 19.56 (-0.05), OFIX: 47.11 (-0.29), HRC: 53.45 (+0.02), OSUR: 6.77 (-0.05)
